• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Esperion Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    7/1/25 8:14:50 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ESPR alert in real time by email
    espr-20250701
    FALSE000143486800014348682025-07-012025-07-01

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of Earliest Event Reported): July 1, 2025

    Esperion Therapeutics, Inc.
    (Exact name of registrant as specified in its charter)
    Delaware001-3598626-1870780
    (State or other jurisdiction of
    incorporation)
    (Commission File Number)(I.R.S. Employer
    Identification No.)

    3891 Ranchero Drive, Suite 150
    Ann Arbor, MI
    (Address of principal executive offices)

    48108
    (Zip Code)

    Registrant’s telephone number, including area code: (734) 887-3903

    Not Applicable
    Former name or former address, if changed since last report

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each classTrading SymbolName of each exchange on which registered
    Common Stock, par value $0.001 per shareESPRNASDAQ Stock Market LLC
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

    Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐




    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.

    On July 1, 2025, upon the recommendation of the Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of Esperion Therapeutics, Inc. (the “Company”) elected Craig Thompson to the Board, effective July 1, 2025. Mr. Thompson will serve as a Class II director with a term expiring at the Company’s annual meeting of stockholders to be held in 2027, at which time he will stand for election by the Company’s stockholders, or until his earlier death, resignation or removal. The Board determined that Mr. Thompson is an independent director as that term is defined by the Securities and Exchange Commission (the “SEC”) and the Nasdaq Stock Market, LLC. Mr. Hoffman will serve as a member of the Compliance Committee, the Nominating and Corporate Governance Committee and the Commercial Committee, until his successor is duly elected and qualified, or until his earlier death, resignation or removal, or until otherwise determined by the Board.

    Since April 2022, Mr. Thompson has been the Chief Executive Officer and a member of the board of directors at Cerevance, LLC, a clinical stage biotechnology company focused on neurodegenerative, psychiatric, and central nervous system-controlled metabolic disorders. Mr. Thompson is also currently a member of the board of directors of NervGen Pharma Corp, a clinical stage biotechnology company focused on developing therapies for neurotrauma and neurologic diseases. From June 2018 to April 2022, Mr. Thompson was previously President & Chief Executive Officer and a member of the board of directors of Neurana Pharmaceuticals, Inc., a biotechnology company focused on the treatment of neuromuscular conditions. Prior to Neurana, Mr. Thompson was President & Chief Executive Officer and a member of the board of directors of Anthera Pharmaceuticals, Inc., a then publicly traded clinical-stage biopharmaceutical company that focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. His previous biotech experience includes serving as Chief Operating Officer for Tetraphase Pharmaceuticals Inc., where he oversaw the development and implementation of the commercial strategy as well as the business development and commercial manufacturing, and as Chief Commercial Officer for Trius Therapeutics, Inc., where he was involved in the acquisition of Trius Therapeutics by Cubist Pharmaceuticals, Inc. for over $700 million, as well as a partnership with Bayer Pharma AG.

    Prior to Trius Therapeutics, Mr. Thompson served in a range of U.S. and global leadership roles of increasing responsibility at Pfizer Inc., including Therapeutic Group Leader of Allergy, Respiratory, Pulmonary Vascular Disease and Inflammation; and he ultimately served as Vice President of Marketing for Pfizer’s Specialty Care Business Unit. While at Pfizer, he led the global commercial development of the torcetrapib/atorvastatin program. Earlier in his career, Mr. Thompson held positions of increasing responsibility in global marketing at Merck & Co., where he was responsible for product management of Zocor, including leading the rollout of the landmark Heart Protection Study. He also was instrumental in the pre-launch planning for Vytorin and Zetia as part of the European partnership between Merck and Schering-Plough. Mr. Thompson holds a Bachelor’s of Commerce degree from McMaster University and an MBA from the University of Notre Dame.

    As a non-employee director, Mr. Thompson will receive cash and equity compensation for his Board service pursuant to its non-employee director compensation program. There are no arrangements or understandings between Mr. Thompson and any other person pursuant to which Mr. Thompson was selected as a director, and there are no transactions between Mr. Thompson and the Company that would require disclosure under Item 404(a) of Regulation S-K. In addition, the Company has entered into an indemnification agreement with Mr. Thompson in connection with his appointment to the Board which is in substantially the same form as that entered into with the existing directors of the Company.

    Item 7.01 Regulation FD Disclosure.

    On July 1, 2025, the Company issued a press release announcing Mr. Thompson’s appointment. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    The information furnished under this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.




    Item 9.01. Financial Statements and Exhibits.

    Exhibit No.Description
    99.1
    Press Release dated July 1, 2025.
    104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.




    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: July 1, 2025Esperion Therapeutics, Inc.
    By:/s/ Sheldon L. Koenig
    Sheldon L. Koenig
    President and Chief Executive Officer


    Get the next $ESPR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ESPR

    DatePrice TargetRatingAnalyst
    12/18/2024$4.00Neutral
    Goldman
    12/17/2024$8.00Overweight
    Cantor Fitzgerald
    6/20/2024$2.50Neutral → Underperform
    BofA Securities
    1/3/2024Buy → Neutral
    BofA Securities
    11/20/2023Neutral
    JP Morgan
    8/1/2023Under Perform → Market Perform
    Northland Capital
    6/15/2023$1.25 → $4.00Underperform → Buy
    BofA Securities
    3/16/2023$1.00Market Perform → Under Perform
    Northland Capital
    More analyst ratings

    $ESPR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

      Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

      3/25/24 4:41:30 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

      Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

      3/25/24 4:41:37 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

      Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

      3/25/24 4:41:29 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ESPR
    Leadership Updates

    Live Leadership Updates

    See more
    • Esperion Appoints Craig Thompson to Board of Directors

      ANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent director. With Mr. Thompson's appointment, Esperion's Board of Directors now comprises eight members. "We are thrilled to welcome Craig to our Board of Directors. With more than two decades of biopharmaceutical industry leadership and a proven track record advancing innovative therapies, Craig brings a wealth of strategic insight and operational expertise that will be invaluable as we continue to expand our impact in cardiovascular and cardiometabolic drug devel

      7/1/25 8:06:21 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

      – Expands Development Portfolio with Introduction of a Novel Program Targeting PSC – – Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across Multiple PSC-Relevant Pre-Clinical Models – – Demonstrates Internal R&D Capabilities with Wholly Owned, Next-Generation Candidates Targeting Liver and Kidney Disease – – Esperion to Webcast R&D Day Event Today at 9:00 a.m. ET – ANN ARBOR, Mich., April 24, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the Company plans to highlight new research supporting its lead development candidates for the treatment of primary sclerosing cholangitis (PSC), a rare and progressive

      4/24/25 8:00:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

      ANN ARBOR, Mich., April 10, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it will host an in-person R&D Day for analysts and investors on April 24, 2025, beginning at 9:00 a.m. ET in New York City. This event will feature presentations from company leadership and key opinion leaders to provide a deep dive into Esperion's research and development strategy. Discussions will highlight Esperion's advancements and novel insights into ATP citrate lyase (ACLY) biology and the therapeutic role these next-generation inhibitors can play in multiple life-threatening diseases such as rare and chronic liver and kidney diseases. Additionally, Esperion will unveil a new indicati

      4/10/25 8:00:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ESPR
    SEC Filings

    See more
    • Esperion Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)

      7/1/25 8:14:50 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Esperion Therapeutics Inc.

      144 - Esperion Therapeutics, Inc. (0001434868) (Subject)

      6/17/25 3:34:11 PM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)

      6/2/25 4:05:52 PM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ESPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Esperion Appoints Craig Thompson to Board of Directors

      ANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent director. With Mr. Thompson's appointment, Esperion's Board of Directors now comprises eight members. "We are thrilled to welcome Craig to our Board of Directors. With more than two decades of biopharmaceutical industry leadership and a proven track record advancing innovative therapies, Craig brings a wealth of strategic insight and operational expertise that will be invaluable as we continue to expand our impact in cardiovascular and cardiometabolic drug devel

      7/1/25 8:06:21 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

      ANN ARBOR, Mich., June 02, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it has entered into a settlement agreement with Hetero USA, Inc. and its affiliates Hetero Labs Limited, Hetero Labs Limited Unit-V, and Honour Lab Limited (together, Hetero USA). This agreement resolves the patent litigation brought by Esperion against Hetero USA in response to Hetero USA' s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to the agreement, Hetero USA has agreed not to market a generic version of NEXLETOL in the United States prior to April 19, 2040, unless certain limite

      6/2/25 8:00:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion to Participate in Upcoming June Investor Conferences

      ANN ARBOR, Mich., May 20, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will be participating in the following webcasted investor events during the month of June, which can be found on our investor relations website. Jefferies Global Healthcare Conference in New York on June 4, 2025, at 1:25 p.m. ET. Goldman Sachs Global Healthcare Conference in Miami on June 9, 2025, at 10:40 a.m. ET. Live webcasts can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company's website for approximately 90 days. Espe

      5/20/25 8:00:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ESPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Esperion Therapeutics with a new price target

      Goldman initiated coverage of Esperion Therapeutics with a rating of Neutral and set a new price target of $4.00

      12/18/24 7:29:57 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Esperion Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Esperion Therapeutics with a rating of Overweight and set a new price target of $8.00

      12/17/24 7:45:32 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion Therapeutics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Esperion Therapeutics from Neutral to Underperform and set a new price target of $2.50

      6/20/24 7:33:38 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ESPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Thompson John Craig

      4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

      7/2/25 8:21:38 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Thompson John Craig

      3 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

      7/2/25 8:18:47 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Looker Benjamin sold $7,398 worth of shares (6,422 units at $1.15), decreasing direct ownership by 2% to 401,241 units (SEC Form 4)

      4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

      6/18/25 6:45:08 PM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ESPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Esperion Therapeutics Inc.

      SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)

      11/14/24 8:42:21 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Esperion Therapeutics Inc.

      SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)

      11/12/24 2:23:13 PM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Esperion Therapeutics Inc.

      SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)

      11/4/24 1:33:59 PM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ESPR
    Financials

    Live finance-specific insights

    See more
    • HLS Therapeutics Announces Q1 2025 Financial Results

      Total Product revenue grew 5% compared to Q1 2024, with growth across both the US and CanadaCanadian Product revenue grew 13% (in local currency) compared to Q1 2024, driven by 34% year-over-year growth in Vascepa net sales Adjusted EBITDA grew 41% (or 78% excluding royalty revenue) compared to Q1 2024HLS expands Cardiovascular portfolio by securing Canadian rights to NEXLETOL® and NEXLIZET® from Esperion TherapeuticsTORONTO, May 8, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three months ended Marc

      5/8/25 6:32:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion Reports First Quarter 2025 Financial Results

      – Q1 2025 Total Revenue of $65.0 Million, a Decrease of 53% Y/Y; Adjusting for One Time Milestone Received in Q1 2024, Total Revenue Grew 63% Y/Y – – Q1 2025 U.S. Net Product Revenue Grew 41% Y/Y to $34.9 Million – – Bempedoic Acid Earned Level 1a Recommendations in the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes – – Expanded Development Portfolio with Introduction of Novel Program Targeting Primary Sclerosing Cholangitis (PSC) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., May 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the first quarter ended March 31, 202

      5/6/25 6:00:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion to Report First Quarter 2025 Financial Results on May 6

      ANN ARBOR, Mich., April 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report first quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial stage biopharmaceutical company f

      4/23/25 8:00:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care